Overview
Sleuth Insights offers an AI-powered biopharma intelligence platform that helps analysts and investors make strategic decisions by leveraging a knowledge graph with over 100 million validated data points from public and proprietary sources. Users can either query the data in natural language, export findings and build dashboards, or rely on done-for-you intelligence from Sleuth’s team of analysts who deliver custom landscapes and strategic briefings. The platform combines automated data connections with analyst-driven analysis to provide tailored competitive intelligence and commercial diligence. Its goal is to shorten the time and effort needed to gather, analyze, and interpret biopharma data for informed decision-making, with pricing based on annual retainers and license needs.
Work here?Claim your company
Simplify's take
What believers are saying
- Sleuth launched from stealth in April 2026 with $8 million led by Bison Ventures.
- Its site says dozens of biopharma companies, including Daiichi Sankyo, already use the platform.
- Updated November 2026 analyses show active product usage and continuous intelligence publishing.
What critics are saying
- Sleuth is still seed-stage after April 2026, so revenue concentration stays high.
- McKinsey, Clarivate, and Citeline already sell adjacent intelligence workflows to biopharma buyers.
- If entity matching or source coverage slips, pharma renewals vanish and the moat collapses.
What makes Sleuth Insights unique
- Sleuth combines analyst-delivered briefs with a self-serve AI biopharma workspace.
- Andrew Pannu brings biopharma BD and corporate development experience from Immunai and Covis Pharma.
- Its knowledge graph traces every answer to primary sources, supporting defensible diligence.
Help us improve and share your feedback! Did you find this helpful?